The emerging state of the art

This book has comprehensively illustrated the current state of the art and discussed open issues in the three pillars of inhaled drug development, in vivo, in vitro and in silico methods that underpin the quality, safety and efficacy of a product. In this chapter, we argue that we have reached a point in the historical development of inhalation therapies, where these three methods will converge in support of integrated in silico tools. As a result, over the next few years we are likely to witness a significant enhancement of the capabilities of in silico methods and inferences for clinic application and drug product development.